廣生堂(300436.SZ):創新藥控股子公司廣生中霖擬增資擴股暨引入投資者
格隆匯1月6日丨廣生堂(300436.SZ)公佈,公司於2023年1月5日召開第四屆董事會第十七次會議及第四屆監事會第十六次會議,審議通過《關於創新藥控股子公司廣生中霖增資擴股暨引入投資者的議案》,為滿足創新藥研發資金需求,加快創新藥物研究進度,同意創新藥控股子公司福建廣生中霖生物科技有限公司(“廣生中霖”)以增資擴股方式引入投資者,同意授權公司及廣生中霖管理層負責簽署與此次交易相關的對應法律文件,以及具體履行協議的相關事宜。
福建省投資開發集團有限責任公司下屬專業投資基金福州創新創科投資合夥企業(有限合夥)(“創新創科”)、寧德市國有資產投資經營有限公司下屬專業產業投資基金寧德市匯聚一號股權投資合夥企業(有限合夥)(“寧德匯聚”)及杭州泰鯤股權投資基金合夥企業(有限合夥)(“杭州泰鯤”)、杭州泰譽四期創業投資合夥企業(有限合夥)(“杭州泰譽四期”)擬合計增資2.2億元,其中3850萬元計入註冊資本,18150萬元計入資本公積。增資完成後,前述投資方合計取得廣生中霖的股權比例為9.9099%。
公司及廣生中霖原股東福州奧泰五期投資合夥企業(有限合夥)、福州奧泰六期投資合夥企業(有限合夥)均放棄此次增資的優先認繳出資權。
此次增資完成後,廣生中霖註冊資本將由3.5億元增加至3.885億元,公司持有廣生中霖股份比例由90.00%下降至81.0811%,廣生中霖仍為公司控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.